Cadence Neuroscience raises $26M to support epilepsy neuromod therapy

2023-05-18

The Angelini Lumira Biosciences Fund led the round. It also included new investors F-Prime Capital, LivaNova USA, Angelini Ventures, Spectrum Financial Services and Mayo Clinic. Series A lead investor, Jazz Venture Partners, also contributed. In connection with the financing, Gerry Brunk of Lumira and Kevin Chu of F-Prime joined Cadence Neuroscience’s board. Cadence develops a novel neuromodulation therapy for treating pediatric and adult patients with focal drug-resistant epilepsy. The therapy utilizes chronic subthreshold cortical stimulation. It modulates EEG biomarkers associated with epilepsy to reduce or eliminate seizures. Chu called the “precise, patient specific” stimulation method Cadence develops “unique and exciting.” “We believe Cadence’s platform solution has the potential to become an important standard of care in drug-resistant epilepsy as well as other difficult-to-treat brain disorders,” said Paolo Di Giorgio, CEO of Angelini Ventures. The company says it plans to use the funds raised to complete pivotal clinical studies and pursue FDA clearance. “The Cadence team has extensive domain expertise in developing active neural implants and conducting human clinical studies in the field,” said Kent Leyde, Cadence co-founder and CEO. “During the last three years, we have been closely collaborating with Mayo Clinic in the design, manufacture, and engineering tests of our therapy system. These efforts are nearing completion and will enable us to begin clinical testing.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构